Research Focus
In many tumors, PI3K inhibitors are ineffective, in part due to the adaptive kinome rewiring and compensatory activation of bypass signaling pathways in response to PI3K inhibition. My focus is on investigating the epigenetic regulation of the PI3K pathway and identifying an effective combination therapy that will disable compensatory bypass routes, overcoming drug resistance.